Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.

ABSTRACT:

Purpose

During preclinical testing, teriparatide caused a dose-dependent increase in the incidence of osteosarcoma in rats. This study compared the incidence rate of osteosarcoma among patients aged ≥65 years treated with teriparatide vs a matched-comparator cohort.

Methods

This population-based comparative-cohort study matched exposure details for each teriparatide user, identified via Medicare Part D prescription claims, and up to four comparators based on age, sex, zip code, date of claim for filled prescription, and number of unique therapeutic classes dispensed. Outcomes were identified via linkage with participating cancer registries. All US state cancer registries were invited to participate.

Results

Overall, 153 316 patients in the teriparatide cohort and 613 

SUBMITTER: Gilsenan A 

PROVIDER: S-EPMC7754479 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature